These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32374504)

  • 1. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy.
    Powell AGMT; Karran A; Blake P; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Aug; 4(4):593-600. PubMed ID: 32374504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma.
    Powell AGMT; Chin C; Coxon AH; Chalishazar A; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Jun; 4(3):416-423. PubMed ID: 32232963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
    Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
    Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.
    Reece-Smith AM; Saunders JH; Soomro IN; Bowman CR; Duffy JP; Kaye PV; Welch NT; Madhusudan S; Parsons SL
    Ann R Coll Surg Engl; 2017 May; 99(5):378-384. PubMed ID: 28462649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
    Sundar R; Ng A; Zouridis H; Padmanabhan N; Sheng T; Zhang S; Lee MH; Ooi WF; Qamra A; Inam I; Hewitt LC; So JB; Koh V; Nankivell MG; Langley RE; Allum WH; Cunningham D; Rozen SG; Yong WP; Grabsch HI; Tan P
    Eur J Cancer; 2019 Dec; 123():48-57. PubMed ID: 31655359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
    Noble F; Lloyd MA; Turkington R; Griffiths E; O'Donovan M; O'Neill JR; Mercer S; Parsons SL; Fitzgerald RC; Underwood TJ;
    Br J Surg; 2017 Dec; 104(13):1816-1828. PubMed ID: 28944954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.
    Davarzani N; Hutchins GGA; West NP; Hewitt LC; Nankivell M; Cunningham D; Allum WH; Smyth E; Valeri N; Langley RE; Grabsch HI
    Histopathology; 2018 Jun; 72(7):1180-1188. PubMed ID: 29465751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis.
    Parry K; van Rossum PS; Haj Mohammad N; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2017 Jan; 43(1):226-233. PubMed ID: 27424786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does a high Mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma?
    Knight WRC; Baker CR; Griffin N; Wulaningsih W; Kelly M; Davies AR; Gossage JA;
    Br J Cancer; 2021 May; 124(10):1653-1660. PubMed ID: 33742143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial.
    Hale MD; Nankivell M; Hutchins GG; Stenning SP; Langley RE; Mueller W; West NP; Wright AI; Treanor D; Hewitt LC; Allum WH; Cunningham D; Hayden JD; Grabsch HI
    Oncotarget; 2016 Nov; 7(47):77565-77575. PubMed ID: 27769054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy.
    Karran A; Blake P; Chan D; Reid TD; Davies IL; Kelly M; Roberts SA; Crosby T; Lewis WG
    Br J Surg; 2014 Apr; 101(5):502-10. PubMed ID: 24615406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin.
    Bott RK; Beckmann K; Zylstra J; Wilkinson MJ; Knight WRC; Baker CR; Kelly M; Maisey N; Qureshi A; Sevitt T; Van Hemelrijck M; Smyth EC; Allum WH; Lagergren J; Gossage JA; Cunningham D; Davies AR;
    Br J Surg; 2020 Dec; 107(13):1801-1810. PubMed ID: 32990343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.
    Davies AR; Myoteri D; Zylstra J; Baker CR; Wulaningsih W; Van Hemelrijck M; Maisey N; Allum WH; Smyth E; Gossage JA; Lagergren J; Cunningham D; Green M;
    Br J Surg; 2018 Nov; 105(12):1639-1649. PubMed ID: 30047556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy.
    Peng YF; Yu WD; Pan HD; Wang L; Li M; Yao YF; Zhao J; Gu J
    World J Gastroenterol; 2015 Feb; 21(6):1851-6. PubMed ID: 25684951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
    Sujendran V; Wheeler J; Baron R; Warren BF; Maynard N
    Br J Surg; 2008 Feb; 95(2):191-4. PubMed ID: 17948302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy Benefits Survival in High-Grade Upper Tract Urothelial Carcinoma: A Propensity Score-Based Analysis.
    Chen L; Ou Z; Wang R; Zhang M; He W; Zhang J; Zu X; Yi L; Xu R; Jiang S; Qi L; Wang L
    Ann Surg Oncol; 2020 Apr; 27(4):1297-1303. PubMed ID: 31853757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of individual surgeon performance metrics as quality assurance measures in oesophagogastric cancer surgery.
    Powell AGMT; Wheat J; Patel N; Chan D; Foliaki A; Roberts SA; Lewis WG;
    BJS Open; 2020 Feb; 4(1):91-100. PubMed ID: 32011808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
    Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
    Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
    Kim S; Paget-Bailly S; Messager M; Nguyen T; Mathieu P; Lamfichekh N; Fein F; Fratté S; Cléau D; Lakkis Z; Jary M; Sakek N; Jacquin M; Foubert A; Bonnetain F; Mariette C; Fiteni F; Borg C
    Eur J Surg Oncol; 2017 Jan; 43(1):218-225. PubMed ID: 27425578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.